Actavis first to market generic prostate cancer drug Bicalutamide in the UK, Germany & France

Actavis, the international generic pharmaceuticals company, recently launched Bicalutamide tablets in the UK, Germany and France. Acuavis Bicalutamide is the first generic version of the oncology drug to be made available in the three markets.

Actavis has launched a generic drug for prostate cancer, Bicalutamide, in the UK, France and Germany.

Bicalutamide, the generic version of AstraZeneca’s Casodex®, is used as a treatment for prostate cancer and will be available in tablet form in 50mg doses in all three markets, as well as in 150mg doses in the UK.

Bicalutamide Actavis was launched on day one, when the brand product’s patent expired; on 8 July in the UK and 9 July in Germany and France. Distribution of the product will commence immediately.

Commenting on the launch of Bicalutamide, Svend Andersen, Executive Vice President of Western Europe Sales, said: “We are pleased to be the first generic pharmaceutical company to bring this product to the market – creating value for patients at a lower price. Bicalutamide is an important product in Actavis’ portfolio. It is used in treating prostate cancer and also in combination with other treatments of malign diseases, prescribed by both hospitals and general practitioners.”

Actavis was able to launch generic Bicalutamide in some of its countries of operation as early as 2007, including the Czech Republic, Slovakia, Poland and Iceland.

Visit the Actavis website at for more information on generic Bicalutamide for prostate cancer.

About Actavis Group
Actavis is one of the world’s leading generic pharmaceutical companies specialising in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in 40 countries, with 11,000 employees.

Actavis Group
Hjordis Arnadottir
Director, External Communications
Tel: (+354) 535 2300 / 840 7476